ASCO 2019 and the future of oncology
ASCO 2019 - Kantar reviews results from phase 3 POLO trial
Lynparza is paving new ground in pancreatic cancer, aiming to establish a maintenance setting and patient segmentation based on a biomarker (gBRCA mt) in first-line metastatic disease.
